Upgrade to SI Premium - Free Trial

BioMarin Pharma (BMRN) Says NEJM Published Open-label Study Showing Brineura Reduced Rate of Clinical Decline of Children with CLN2 Disease

April 24, 2018 2:32 PM
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the New England Journal of Medicine (NEJM) published updated results from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles